Drugline is a fortnightly electronic drug bulletin for health professionals.


Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.

Ertugliflozin for Type 2 Diabetes

Drugline Volume 359

Ertugliflozin is the latest sodium-glucose co-transporter-2 (SGLT-2) inhibitor available in Australia. This medication helps to regulate blood glucose levels in type 2 diabetes by increasing urinary glucose excretion. The following products containing ertugliflozin were…

Read more

Monoclonal Antibody for Migraines

Drugline Volume 358

Erenumab is a human monoclonal antibody indicated for migraine prophylaxis in adults. This new medication potently and specifically competes with calcitonin gene-related peptide (CGRP) to inhibit its activity at the CGRP receptor. CGRP is…

Read more

Pholcodine and Anaphylaxis

Drugline Volume 357

While patients undergoing anaesthesia in Australia continue to enjoy good clinical outcomes, anaesthesia-related anaphylaxis remains a significant cause of morbidity and mortality. Neuromuscular blocking agents (NMBAs) are the most commonly implicated drug class, involved…

Read more

Minimising Harms Associated with Pregabalin

Drugline Volume 356

Growing evidence suggests an increase in the misuse of pregabalin in Australia. Coronial data identifies 88 pregabalin-associated deaths in New South Wales between 2005 and 2016, while Victoria saw a 12-fold increase in pregabalin-related…

Read more

Neuromuscular Blocking Agents

Drugline Volume 355

The Therapeutic Goods Administration (TGA) has introduced new warnings for neuromuscular blocking agents (NMBA). NMBAs available in Australia are atracurium, cisatracurium, mivacurium, pancuronium, rocuronium, vecuronium, and suxamethonium. These medications are considered high-risk as unintentional…

Read more

Pembrolizumab Listing Extended

Drugline Volume 354

From 1st November 2018, pembrolizumab is available on the Pharmaceutical Benefits Scheme (PBS) for the first-line treatment of metastatic non-small cell lung cancer. This is in addition to its original listing for Stage III…

Read more
Load More

January 2019

December 2018

October 2018

September 2018

August 2018

July 2018

April 2018

January 2018

December 2017

September 2017

Thunderstorm Asthma (Sep. 21 2017)

The Efficacy of Perampanel (Sep. 08 2017)

July 2017

June 2017

April 2017

March 2017

November 2016

September 2016

August 2016

April 2016

November 2015

Viekira Pak for Hepatitis C (Nov. 19 2015)

Micafungin (Nov. 05 2015)

October 2015

Dabigatran Antidote on the Horizon (Oct. 22 2015)

Akynzeo® (Oct. 08 2015)

September 2015

May 2015

April 2015

Victoza (liraglutide) (Apr. 23 2015)

Ultibro Breezhaler 100/50 (Apr. 09 2015)

March 2015

February 2015

December 2014

November 2014

October 2014

September 2014

World Pharmacist Day (Sep. 24 2014)

National Stroke Week (Sep. 11 2014)

August 2014

July 2014

Breo™ Ellipta® (Jul. 31 2014)

Use of Prolia® in Men (Jul. 17 2014)

Adcetris® (brentuximab vedotin) (Jul. 03 2014)

April 2014

March 2014

September 2013

August 2013

July 2013

June 2013

Riluzole for Motor Neurone Disease (Jun. 20 2013)

Mycamine (Jun. 06 2013)

May 2013

HPV Vaccine (May. 23 2013)

World Lupus Day (May. 09 2013)

December 2012

November 2012

August 2012